1.Fischer, G, Smevik, B, Novoa, JCR, Suares, FJO, Kramer, HH, Bjornstad, PG. Catheter-based treatment with the Amplatzer devices in alien positions. Catheter Cardiovasc Interv 2009; 73:669–675.
2.Mahmoud, HT, Santoro, G, Capogrosso, C, Russo, MG. Off-label use of Amplatzer Duct Occluder II additional sizes. J Cardiovasc Med 2017; 18:436–442.
3.Riede, F-T, Kostelka, M, Dähnert, I. Transcatheter aortic valve closure to treat severe aortic regurgitation in a patient failing stage I palliation for hypoplastic left heart syndrome. Catheter Cardiovasc Interv 2009; 74:913–915.
4.Elling, R, Stiller, B, Grohmann, J. Transcatheter device occlusion of the left ventricular outflow tract as treatment for severe aortic regurgitation in hypoplastic left heart syndrome. Catheter Cardiovasc Interv 2015; 86:463–466.
5.Eicken, A, Georgiev, S, Balling, G, Schreiber, C, Hager, A, Hess, J. Neonatal balloon aortic valvuloplasty-predictive value of current risk score algorithms for treatment strategies. Catheter Cardiovasc Interv 2010; 76:404–410.
6.Rhodes, LA, Colan, SD, Perry, SB, Jonas, RA, Sanders, SP. Predictors of survival in neonates with critical aortic stenosis. Circulation 1991; 84:2325–2335.
7.Whitlock, RP, Sun, JC, Fremes, SE, Rubens, FD, Teoh, KH. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:576–600.
8.Simsic, JM, Bradley, SM, Stroud, MR, Atz, AM. Risk factors for interstage death after the Norwood Procedure. Pediatr Cardiol 2005; 26:400–403.
9.Delmo Walter, EM, Hübler, M, Alexi-Meskishvili, V, et al. Staged surgical palliation in hypoplastic left heart syndrome and its variants. J Card Surg 2009; 24:383–391.
10.Rudd, NA, Frommelt, MA, Tweddell, JS, et al. Improving interstage survival after Norwood operation: outcomes from 10 years of home monitoring. J Thorac Cardiovasc Surg 2014; 148:1540–1547.